Technical Data
SOCS 1, CT (Suppressor of Cytokine Signalling 1, Janus kinase (JAK) binding protein, STAT-induced STAT inhibitor, SSI-1)
The Suppressor of cytokine signaling (SOCS) and cytokine-inducible SH2 proteins are a family of intracellular proteins which regulate the immune cell responses to cytokines (1). SOCS1 acts to suppress dendritic cell (DC) as well as T cell hyperactivation following cytokine signaling by inhibiting JAK tyrosine kinase, a kinase necessary for type I and II cytokine receptors to initiate signaling, by directly binding to the catalytic domain of the kinase (2). SOCS1 also possesses E3 ubiquitin protein ligase activity that results in the polyubiquitination of its target proteins and subsequent degradation by the proteosome (3). It is through this method that SOCS1 negatively regulates signaling by Toll-like receptors TLR2 and TLR4 by mediating the degradation of the TLR signaling adaptor protein TIRAP (4).

Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1-2ug/ml. See S1040-01F1 for control peptide.
Optimal dilutions to be determined by the researcher.

Positive Control:
Human spleen cell lysate

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
PabIgGAffinity Purified
100ug-20CBlue IceHumanRabbit
As reported
15 amino acid peptide from near the carboxy terminus of human SOCS1 (UniProt CAB92528)
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, 0.02% sodium azide.
Recognizes human SOCS1. Species Crossreactivity: Mouse and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Rakesh K and Agrawal DK. Controlling cytokine signaling by constitutive inhibitors. Biochem. Pharm. 2005; 70:649-57.
2. O'Shea JJ, Gadina M, and Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109:S121-31.
3. Kile BT, Schulman BA, Alexander WS, et al. The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 2002; 27:235-41.
4. Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively mediates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 2006; 7:148-55.